How to translate pharmacokinetic data into dosing recommendations

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10319899" target="_blank" >RIV/00216208:11110/15:10319899 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10319899
Result on the web
<a href="http://dx.doi.org/10.1159/000364989" target="_blank" >http://dx.doi.org/10.1159/000364989</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000364989" target="_blank" >10.1159/000364989</a>

Result language
angličtina
Original language name
How to translate pharmacokinetic data into dosing recommendations
Original language description
Pharmacotherapy in children is challenging due to limited knowledge of the influence of physiological changes on drug exposure and response. Differences in drug pharmacokinetics are often considered the main drivers of age-related differences in dose requirements in neonates and young infants. Pharmacokinetic parameters in these young children can be derived from a 'population analysis' of drug concentration measurements in the blood at various time points after drug administration. A major advantage ofperforming a population analysis is that it allows investigations into betweensubject variability. Patient characteristics that can describe patterns in the variability of pharmacokinetic parameters can be used to predict these pharmacokinetic parameters in other patients within the same population. The distribution volume of a drug is the main driver of peak concentrations, whereas drug clearance is the driver of steady state concentrations. Information on how these parameters differ b
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FG - Paediatrics
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)